

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,
Petitioner

v.

GENZYME CORPORATION,
Patent Owner.

Case: IPR2026-00150
Patent No. 12,031,894

NOTICE OF DEPOSITION OF STEVEN BERKOWITZ, PH.D.

In accordance with 37 C.F.R. § 42.53, Patent Owner Genzyme Corporation (“Patent Owner”), provides notice to Petitioner Sarepta Therapeutics, Inc. (“Petitioner”) that it will conduct a deposition of Dr. Steven Berkowitz. The deposition will take place on July 29, 2026, commencing at 9:00 am ET, at the office of Quinn Emanuel Urquhart & Sullivan, LLP 111 Huntington Ave, Suite 520, Boston, MA 02199, and will continue until its completion. The deposition will be recorded by stenographic and/or audiovisual means before an officer duly authorized by law to administer oaths under 35 U.S.C. § 23. In accordance with 37 C.F.R. § 42.53(d)(1), the parties have conferred and have agreed upon this date and location for the deposition.

Dated: July 15, 2026

/ Blaine M. Hackman /
Blaine M. Hackman, Ph.D.
Reg. No. 67,479
Counsel for Patent Owner

CERTIFICATE OF SERVICE

I certify that today in:

Sarepta Therapeutics, Inc., v. Genzyme Corp., IPR2026-00150
(U.S. Patent 12,013,894)

I caused to be served a copy of:

NOTICE OF DEPOSITION OF STEVEN BERKOWITZ, PH.D.

upon:

Sarepta Therapeutics, Inc. c/o:

robertwilson@quinnemanuel.com
annetoker@quinnemanuel.com
jimglass@quinnemanuel.com

via:

electronic service to the email addresses above.

Dated: July 15, 2026

By: / Blaine M. Hackman /
Blaine Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
blaine.hackman@dechert.com